P. E. Thorpe, Vascular Targeting Agents as Cancer Therapeutics, Clinical Cancer Research, vol.10, issue.2, pp.415-427, 2004.
DOI : 10.1158/1078-0432.CCR-0642-03

D. Neri and R. Bicknell, Tumour vascular targeting, Nature Reviews Cancer, vol.74, issue.6, pp.436-446, 2005.
DOI : 10.1016/j.ab.2003.09.040

C. Kanthou and G. M. Tozer, Tumour targeting by microtubule-depolymerising vascular disrupting agents, Expert Opinion on Therapeutic Targets, vol.6, issue.11, pp.1443-1457, 2007.
DOI : 10.1083/jcb.200303082

C. A. Honstvet and P. F. Jones, Targeting Tumour Vasculature as a Cancer Treatment, Computational and Mathematical Methods in Medicine, vol.8, issue.1, pp.1-9, 2007.
DOI : 10.1080/17486700701298319

C. Kanthou and G. M. Tozer, Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies, International Journal of Experimental Pathology, vol.92, issue.4 Suppl. 1, pp.284-294, 2009.
DOI : 10.1111/j.1365-2613.2009.00651.x

V. L. Heath and R. Bicknell, Anticancer strategies involving the vasculature, Nature Reviews Clinical Oncology, vol.68, issue.7, pp.395-404, 2009.
DOI : 10.1038/nrclinonc.2009.52

L. G. Daenen, J. M. Roodhart, Y. Shaked, and E. E. Voest, Vascular Disrupting Agents (VDAs) in Anticancer Therapy, Current Clinical Pharmacology, vol.5, issue.3, p.178, 2010.
DOI : 10.2174/157488410791498815

G. M. Tozer, C. Kanthou, C. S. Parkins, and S. A. Hill, The biology of the combretastatins as tumour vascular targeting agents, International Journal of Experimental Pathology, vol.81, issue.Suppl. 1, pp.21-38, 2002.
DOI : 10.1046/j.1365-2613.2002.00211.x

G. M. Tozer, C. Kanthou, and B. C. Baguley, Disrupting tumour blood vessels, Nature Reviews Cancer, vol.48, issue.8, pp.423-435, 2005.
DOI : 10.1038/sj.bjc.6690416

R. S. Kerbel and N. , Tumor Angiogenesis, New England Journal of Medicine, vol.358, issue.19, pp.2039-2049, 2008.
DOI : 10.1056/NEJMra0706596

D. W. Siemann, The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents, Cancer Treatment Reviews, vol.37, issue.1, pp.63-74, 2011.
DOI : 10.1016/j.ctrv.2010.05.001

R. P. Mason, D. Zhao, L. Liu, M. L. Trawick, and K. G. Pinney, A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment, Integrative Biology, vol.8, issue.4, pp.375-387, 2011.
DOI : 10.1039/c0ib00135j

G. R. Pettit, S. B. Singh, E. Hamel, C. M. Lin, D. S. Alberts et al., Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4, Experientia, vol.65, issue.2, pp.209-211, 1989.
DOI : 10.1007/BF01954881

E. Aprile, G. C. Del-grosso, G. Tron, and . Grosa, In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver Microsomes, Drug Metabolism and Disposition, vol.35, issue.12, pp.2252-2261, 2007.
DOI : 10.1124/dmd.107.016998

N. Nam, Combretastatin A-4 Analogues as Antimitotic Antitumor Agents, Current Medicinal Chemistry, vol.10, issue.17, pp.1697-1722, 2003.
DOI : 10.2174/0929867033457151

A. Cirla and J. Mann, Combretastatins: from natural products to drug discovery, Natural Product Reports, vol.20, issue.6, pp.558-564, 2003.
DOI : 10.1039/b306797c

H. P. Hsieh, J. P. Liou, and N. Mahindroo, Pharmaceutical Design of Antimitotic Agents Based on Combretastatins, Current Pharmaceutical Design, vol.11, issue.13, pp.1655-1677, 2005.
DOI : 10.2174/1381612053764751

G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca et al., Medicinal Chemistry of Combretastatin A4:?? Present and Future Directions, Journal of Medicinal Chemistry, vol.49, issue.11, pp.3033-3044, 2006.
DOI : 10.1021/jm0512903

A. Brancale and R. Silvestri, Indole, a core nucleus for potent inhibitors of tubulin polymerization, Medicinal Research Reviews, vol.428, issue.2, pp.209-238, 2007.
DOI : 10.1002/med.20080

Y. Shan, J. Zhang, Z. Liu, M. Wang, and Y. Dong, Developments of Combretastatin A-4 Derivatives as Anticancer Agents, Current Medicinal Chemistry, vol.18, issue.4, pp.523-538, 2011.
DOI : 10.2174/092986711794480221

M. Marrelli, F. Conforti, G. A. Statti, X. Cachet, S. Michel et al., Biological Potential and Structure-Activity Relationships of Most Recently Developed Vascular Disrupting Agents: An Overview of New Derivatives of Natural Combretastatin A-4, Current Medicinal Chemistry, vol.18, issue.20, pp.3035-3081, 2011.
DOI : 10.2174/092986711796391642

K. Ohsumi, T. Hatanaka, K. Fujita, R. Nakagawa, Y. Fukuda et al., Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues, Bioorganic & Medicinal Chemistry Letters, vol.8, issue.22, pp.3153-3158, 1998.
DOI : 10.1016/S0960-894X(98)00579-4

K. Odlo, J. Fournier-dit-chabert, S. Ducki, O. A. Gani, I. Sylte et al., 1,2,3-Triazole analogs of combretastatin A-4 as potential microtubule-binding agents, Bioorganic & Medicinal Chemistry, vol.18, issue.18, pp.6874-6885, 2010.
DOI : 10.1016/j.bmc.2010.07.032

Ø. W. Akselsen, K. Odlo, J. Cheng, G. Maccari, M. Botta et al., Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1, Bioorganic & Medicinal Chemistry, vol.20, issue.1, pp.234-242, 2012.
DOI : 10.1016/j.bmc.2011.11.010

L. Cafici, T. Pirali, F. Condorelli, E. Del-grosso, A. Massarotti et al., Solution-Phase Parallel Synthesis and Biological Evaluation of Combretatriazoles, Journal of Combinatorial Chemistry, vol.10, issue.5, pp.732-740, 2008.
DOI : 10.1021/cc800090d

D. Dauzonne and R. Royer, A versatile synthesis of 1-aryl-2-nitro-3-(3,4,5-trimethoxyphenyl)propenes as precursors of novel mescaline derivatives., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.34, issue.4, pp.1628-1633, 1986.
DOI : 10.1248/cpb.34.1628

R. B. Ravelli, B. Gigant, P. A. Curmi, I. Jourdain, S. Lachkar et al., Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain, Nature, vol.428, issue.6979, pp.198-202, 2004.
DOI : 10.1038/nature02393

A. Massaroti, A. Coluccia, R. Silvestri, G. Sorba, and A. Brancale, The Tubulin Colchicine Domain: a Molecular Modeling Perspective, ChemMedChem, vol.23, issue.1, pp.33-42, 2012.
DOI : 10.1002/cmdc.201100361

G. Jones, P. Willet, and R. C. Glen, Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation, Journal of Molecular Biology, vol.245, issue.1, pp.43-53, 1995.
DOI : 10.1016/S0022-2836(95)80037-9

R. Álvarez, C. Álvarez, F. Mollinedo, B. G. Sierra, M. Medarde et al., Isocombretastatins A: 1,1-Diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds, Bioorganic & Medicinal Chemistry, vol.17, issue.17, pp.6422-6431, 2009.
DOI : 10.1016/j.bmc.2009.07.012

A. K. Sinhababu and R. T. Bordchardt, Silica gel-assisted reduction of nitrostyrenes to 2-aryl-1-nitroalkanes with sodium borohydride, Tetrahedron Letters, vol.24, issue.3, pp.227-230, 1983.
DOI : 10.1016/S0040-4039(00)81371-4

C. J. Edgell, C. C. Mcdonald, and J. B. Graham, Permanent cell line expressing human factor VIII-related antigen established by hybridization., Proceedings of the National Academy of Sciences, vol.80, issue.12, pp.3734-3737, 1983.
DOI : 10.1073/pnas.80.12.3734

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC394125/pdf

). J. Sadowski and J. Gasteiger, )CORINA ? Fast Generation of High-Quality 3D Molecular Models: http://www.molecular-networks.com/products/corina [63] Schrödinger Suite, Chem. Rev, vol.93, issue.1, p.2012, 1993.

M. C. Bissery, P. Vrignaud, F. Lavelle, and G. G. Chabot, Preclinical Antitumor Activity and Pharmacokinetics of Irinotecan (CPT-11) in Tumor-bearing Mice, Annals of the New York Academy of Sciences, vol.35, issue.1 The Camptothe, pp.173-180, 1996.
DOI : 10.1016/0378-4347(92)80156-K